In patients with heart failure, SGLT2 inhibitors after TAVI are associated with major risk reductions in a clinical trial ...
As of Tuesday, April 01, scPharmaceuticals Inc.’s SCPH share price has dipped by 11.41%, which has investors questioning if this is right time to buy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback